Post Test and Evaluation Form Please note that to receive credit you must achieve a score of at least 70%. Certificate of Credit will be emailed within 4 weeks of successful completion of the activity. Post-Activity Test Question Title 1. The presence of toxigenic C. difficile in the stool always indicates a C. difficile infection (CDI). True False Question Title 2. Characteristics of the hypervirulent BI/NAP1/027 strain of C. difficile include all of the following except: Production of Toxin A and Toxin B High-level resistance to fluoroquinolones Production of a metallo-beta-lactamase Production of binary toxin Question Title 3. Since the emergence and spread of the hypervirulent strain of C. difficile in the early 2000s, all of the following are true except: A greater number of patients with CDI are undergoing colostomy or colectomy The number of CDI infections in the community has increased The mortality rate among the elderly (>65 years) with CDI has remained unchanged The number of CDI cases in long-term care facilities has increased Question Title 4. The use of which of the following antimicrobials poses the greatest risk for C. difficile infection? Vancomycin Cephalosporins Carbapenems Aminoglycosides Question Title 5. Clinical study evidence has shown that the recurrence rate of an initial C. difficile infection following metronidazole or vancomycin treatment is approximately: 5% 20% 50% 75% Question Title 6. Patient factors that predict severe outcomes in CDI include all of the following except: Older age Lack of concomitant antimicrobial exposure Elevated WBC Elevated creatinine Question Title 7. According to the current IDSA guidelines, first-line therapy for an initial episode of severe CDI is: Metronidazole Vancomycin Probiotics Rifaximin Question Title 8. Clinical trials demonstrated that, compared to vancomycin, the use of fidaxomicin in the treatment of CDI resulted in significantly: Higher overall clinical cure rates Higher clinical cure rates for moderate-to-severe CDI only Lower clinical cure rates in patients with mild infection Lower rates of recurrent infection Question Title 9. An effective treatment option for a patient with multiple CDI episodes is: Nitazoxanide C. difficile vaccine Fecal microbiota transplantation Probiotics plus metronidazole Question Title 10. C.difficile infection recurrence is defined as a re-onset of symptoms plus: Positive stool test for C.difficile Positive test for presence of toxin White blood cell count >10,000 Either Positive stool test for C.difficile or Positive test for presence of toxin Next
